Arax Advisory Partners’s Vera Therapeutics VERA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.39K Sell
43
-24
-36% -$839 ﹤0.01% 4968
2026
Q2
$2.88K Buy
67
+50
+294% +$1.86K ﹤0.01% 4727
2026
Q1
$684 Buy
17
+8
+89% +$345 ﹤0.01% 3369
2025
Q4
$456 Sell
9
-33
-79% -$1.17K ﹤0.01% 3625
2025
Q3
$1.22K Buy
+42
New +$971 ﹤0.01% 3212
2024
Q4
– Sell
-81
Closed -$3.58K – 2759
2024
Q3
$3.58K Hold
81
– – ﹤0.01% 1851
2024
Q2
$2.93K Buy
+81
New +$3.21K ﹤0.01% 1822

Other funds holding VERA

Arax Advisory Partners's VERA Position: Q3 2026 in Review

Arax Advisory Partners reduced its Vera Therapeutics (VERA) stake by 36% in Q3 2026, selling an estimated $839 and leaving 43 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4968.

Arax Advisory Partners first reported a position in VERA in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.58K in Q3 2024. 224 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

  • Arax Advisory Partners held 43 shares of Vera Therapeutics worth $1.39K as of Q3 2026.
  • Arax Advisory Partners sold 24 Vera Therapeutics shares in Q3 2026, an estimated $839.
  • Vera Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4968 holding.
  • Arax Advisory Partners first reported a position in Vera Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Vera Therapeutics position peaked at $3.58K in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.